Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Fusion Pharmaceuticals Inc (FUSN)

Fusion Pharmaceuticals Inc (FUSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 131,909
  • Shares Outstanding, K 43,391
  • Annual Sales, $ 1,440 K
  • Annual Income, $ -81,050 K
  • 60-Month Beta -0.04
  • Price/Sales 89.80
  • Price/Cash Flow N/A
  • Price/Book 0.65
Trade FUSN with:

Options Overview Details

View History
  • Implied Volatility 109.15% ( +17.25%)
  • Historical Volatility 85.91%
  • IV Percentile 75%
  • IV Rank 7.92%
  • IV High 911.80% on 08/15/22
  • IV Low 40.08% on 02/15/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 128
  • Open Int (30-Day) 101

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.52
  • Number of Estimates 6
  • High Estimate -0.48
  • Low Estimate -0.58
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -15.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.11 +51.92%
on 08/30/22
3.70 -13.38%
on 09/14/22
+0.98 (+43.79%)
since 08/26/22
3-Month
1.99 +61.06%
on 08/10/22
3.70 -13.38%
on 09/14/22
+0.45 (+16.55%)
since 06/24/22
52-Week
1.99 +61.06%
on 08/10/22
8.73 -63.29%
on 01/19/22
-5.15 (-61.66%)
since 09/24/21

Most Recent Stories

More News
Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why

Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

MRK : 86.16 (-0.71%)
CORT : 24.82 (-1.04%)
FUSN : 3.19 (+5.06%)
AYLA : 1.0500 (+5.64%)
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...

FUSN : 3.19 (+5.06%)
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...

FUSN : 3.19 (+5.06%)
Pacira (PCRX) Up on Data From Exparel Label Expansion Study

Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.

PCRX : 52.55 (-0.59%)
FUSN : 3.19 (+5.06%)
ASRT : 2.18 (+2.35%)
AYLA : 1.0500 (+5.64%)
Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...

MS : 79.52 (-2.44%)
FUSN : 3.19 (+5.06%)
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...

FUSN : 3.19 (+5.06%)
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3

/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as...

FUSN : 3.19 (+5.06%)
After Plunging 14.9% in 4 Weeks, Here's Why the Trend Might Reverse for Fusion Pharmaceuticals Inc. (FUSN)

Fusion Pharmaceuticals Inc. (FUSN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

FUSN : 3.19 (+5.06%)
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

FUSN : 3.19 (+5.06%)
RDUS : 10.08 (-0.20%)
Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates

/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision...

FUSN : 3.19 (+5.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company focused on developing radiopharmaceuticals as precision medicines. The compnay's lead program includes FPI-1434, which is in clinical trial. Fusion Pharmaceuticals Inc. is based in Hamilton, Canada.

See More

Key Turning Points

3rd Resistance Point 3.21
2nd Resistance Point 3.15
1st Resistance Point 3.09
Last Price 3.19
1st Support Level 2.97
2nd Support Level 2.91
3rd Support Level 2.85

See More

52-Week High 8.73
Fibonacci 61.8% 6.16
Fibonacci 50% 5.36
Fibonacci 38.2% 4.56
Last Price 3.19
52-Week Low 1.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar